All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During ASCO 2019, Chicago, US, Alison J Moskowitz, Memorial Sloan Kettering Cancer Center, New York, US, spoke to the Lymphoma Hub about pre-transplant salvage options: bringing conventional versus novel combinations to practice.
Dr. Moskowitz explains that the general approach for a patient that has relapsed or refactor disease after their frontline treatment for Hodgkin lymphoma (HL) is to give some kind of second-line therapy followed by consolidation with an autologous stem cell transplant and the choice of treatment is dependant upon the institution treating the patient. These treatments may include traditional therapies such as ICE, chemotherapy, or DHAP based regimes. However, now that there are newer regimes available for HL such as rituximab and checkpoint inhibitors these are now being considered when treating second-line therapy patients.
Pre-transplant salvage options: bringing conventional versus novel combinations to practice
Lymphoma Hub Satellite Symposium 2019 | DLBCL - chemotherapy-free regimens - Professor Ulrich Jäger
Professor Ulrich Jäger, Medical University of Vienna, Vienna, AT, summarized that the status of DLBCL treatments, with chemotherapy still firmly the...
What is the future of maintenance therapy in relapsed Hodgkin's lymphoma?
Alex Francisco Herrera, City of Hope National Medical Center, Duarte, US, spoke to the Lymphoma Hub about the future of post-transplant maintenance therapies in Hodgkin's...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox